Compare with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ZIM LABORATORIES vs VENUS REMEDIES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ZIM LABORATORIES VENUS REMEDIES ZIM LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x 39.2 6.1 640.3% View Chart
P/BV x 1.5 1.3 118.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ZIM LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    ZIM LABORATORIES
Mar-21
VENUS REMEDIES
Mar-21
ZIM LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs131314 41.8%   
Low Rs5322 238.1%   
Sales per share (Unadj.) Rs189.2444.2 42.6%  
Earnings per share (Unadj.) Rs4.550.1 9.0%  
Cash flow per share (Unadj.) Rs14.278.6 18.1%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %00-  
Book value per share (Unadj.) Rs99.0313.2 31.6%  
Shares outstanding (eoy) m16.2412.34 131.6%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x0.50.4 128.7%   
Avg P/E ratio x20.53.4 608.7%  
P/CF ratio (eoy) x6.52.1 302.9%  
Price / Book Value ratio x0.90.5 173.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,4972,075 72.1%   
No. of employees `000NANA-   
Total wages/salary Rs m358460 77.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,0735,481 56.1%  
Other income Rs m23196 11.9%   
Total revenues Rs m3,0965,678 54.5%   
Gross profit Rs m346772 44.8%  
Depreciation Rs m158353 44.8%   
Interest Rs m109130 83.7%   
Profit before tax Rs m102486 21.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m29-132 -22.1%   
Profit after tax Rs m73618 11.8%  
Gross profit margin %11.314.1 79.9%  
Effective tax rate %28.5-27.2 -104.7%   
Net profit margin %2.411.3 21.1%  
BALANCE SHEET DATA
Current assets Rs m1,9182,316 82.8%   
Current liabilities Rs m1,420974 145.8%   
Net working cap to sales %16.224.5 66.1%  
Current ratio x1.42.4 56.8%  
Inventory Days Days1625 63.0%  
Debtors Days Days858213 402.3%  
Net fixed assets Rs m1,3043,243 40.2%   
Share capital Rs m162123 131.6%   
"Free" reserves Rs m1,4453,742 38.6%   
Net worth Rs m1,6083,865 41.6%   
Long term debt Rs m218468 46.6%   
Total assets Rs m3,2225,559 58.0%  
Interest coverage x1.94.7 41.0%   
Debt to equity ratio x0.10.1 112.1%  
Sales to assets ratio x1.01.0 96.7%   
Return on assets %5.713.5 42.0%  
Return on equity %4.616.0 28.5%  
Return on capital %11.614.2 81.5%  
Exports to sales %67.40-   
Imports to sales %4.10-   
Exports (fob) Rs m2,072NA-   
Imports (cif) Rs m127NA-   
Fx inflow Rs m2,1400-   
Fx outflow Rs m1270-   
Net fx Rs m2,0120-   
CASH FLOW
From Operations Rs m3191,326 24.0%  
From Investments Rs m-59557 -10.6%  
From Financial Activity Rs m-260-1,622 16.0%  
Net Cashflow Rs m-1269 -0.3%  

Share Holding

Indian Promoters % 33.3 40.8 81.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.3 -  
FIIs % 0.0 0.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 66.7 59.2 112.8%  
Shareholders   3,646 18,231 20.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ZIM LABORATORIES With:   SUN PHARMA    LUPIN    CIPLA    AUROBINDO PHARMA    DR. REDDYS LAB    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

VENUS REMEDIES 2020-21 Annual Report Analysis (Annual Result Update)

Nov 2, 2021 | Updated on Nov 2, 2021

Here's an analysis of the annual report of VENUS REMEDIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ZIM LABORATORIES SHARE PRICE


Jan 21, 2022 (Close)

TRACK ZIM LABORATORIES

  • Track your investment in ZIM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ZIM LABORATORIES

ZIM LABORATORIES 5-YR ANALYSIS

COMPARE ZIM LABORATORIES WITH

MARKET STATS